All patients received diuretics as a combination therapy of spironolactone and furosemide.
Thirty-one (66%) patients received metronidazole as first line treatment, 15 (32%) received vancomycin, and two patients received a combination therapy.
Overall, 12 strains (26.1%) were resistant to fluconazole (>8 μg/ml) and 8 (17.4%) had an MIC >1 μg/ml for amphotericin B. Twenty-three patients received combination amphotericin B and fluconazole as their initial antifungal therapy, 17 were given amphotericin B only, five received fluconazole only, and one received a combination of amphotericin B and flucytosine.
Precise supplementation was determined in all patients with respiratory and/or cardiovascular failure, as all received a combination of quantifiable enteral (via nasogastric tube) and intravenous supplementation.
In all, 49 patients with MBC received, as first-line treatment, a combination regimen consisting of i.v. vinorelbine 25 mg m−2 plus epirubicin 90 mg m−2 given on day 1, and oral vinorelbine 60 mg m−2 on day 8 (or day 15 if neutrophils <1500 mm−3) every 3 weeks, in an open-label, multicentre phase II study.
These four groups on HF diet were as follows: HF group – control (HF), R1 group received orally low dose of resveratrol; R2 group received orally low dose of rapamune; and R3 group received a combination of resveratrol and rapamune, as described previously (Leontieva et al., 2013c).
Patients receiving more than two antibiotics, and who received at minimum a combination that was considered guideline concordant, were classified as having received other guideline-concordant regimes.
He received additional volume as a combination of crystalloid and colloid; the resulting CVP was 15 mmHg.
Meanwhile, 40.7% of the fluoroquinolone group received a third-generation cephalosporin as combination therapy, 22.2% received a carbapenem, and 25.9% received piperacillin-tazobactam. Mortality in the ICU was significantly lower for subjects who received a combination therapy with macrolides compared with patients who received quinolones (26.1% vs. 46.3%, p < 0.05).
PDC was calculated for all schizoaffective disorder-related medications received during the follow-up period, irrespective of whether these medications were received as monotherapy or as combination therapy.
